A clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differences.

CONTEXT The World Health Organization classification recommends categorizing grade 3 follicular lymphomas based on the presence of centrocytes (grade 3A) or of sheets of centroblasts (grade 3B). The clinical significance of this practice is not known. OBJECTIVE To determine whether grade 3 follicular lymphoma subtype is associated with prognosis. DESIGN Multi-institutional retrospective case series. MAIN OUTCOME MEASURE Overall survival. RESULTS Forty-five cases of grade 3 follicular lymphoma without diffuse large B-cell lymphoma were studied (35 cases of grade 3A, 10 cases of grade 3B) from 21 men and 24 women (median age, 67 years; mean age, 63.8 years; range, 26-86 years). Follow-up information from the time of diagnosis was available in all patients, with a median follow-up time of 24 months (mean, 34 months; range, 2- 115 months). Treatment information was available in 40 patients. There was no difference in age (P =.45, Wilcoxon test) or stage (P =.76, Fisher exact test) between patients with follicular lymphoma of grade 3A or grade 3B. Furthermore, the Cochran-Armitage test for trends showed no evidence that the proportion of patients with follicular lymphoma grade 3A or 3B increased or decreased with increasing stage at presentation. Kaplan-Meier analysis showed a median overall survival of 44 months from the time grade 3 follicular lymphoma was diagnosed, with no significant difference between cases diagnosed as grade 3A or grade 3B (P =.14, log-rank test). Univariable Cox proportional hazards modeling showed no evidence that an anthracycline-containing chemotherapy regimen or history of lower grade follicular lymphoma affected overall survival. CONCLUSIONS In this retrospective series, subclassification of grade 3 follicular lymphoma into type 3A and 3B categories had limited clinical and prognostic significance. However, the study was limited by lack of statistical power. Since morphology often provides clues for progress in defining biologic differences, subtyping may still be useful, particularly in the setting of prospective clinical studies.

[1]  D. Hochhauser,et al.  Non‐Hodgkin's Lymphomas , 2007 .

[2]  R B Mann,et al.  Criteria for the cytologic subclassification of follicular lymphomas: A Proposed alternative method , 2007, Hematological oncology.

[3]  W. Chan,et al.  A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. , 2003, Blood.

[4]  E. Haralambieva,et al.  Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. , 2003, Blood.

[5]  A. Rosenwald,et al.  Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. , 2002, Blood.

[6]  S. Perkins,et al.  Decreased CD10 expression in grade III and in interfollicular infiltrates of follicular lymphomas. , 2001, American journal of clinical pathology.

[7]  H. Kantarjian,et al.  Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[9]  W. Chan,et al.  Clinical Significance of the t(14;18) And BCL2 Overexpression in Follicular Large Cell Lymphoma , 2000, Leukemia & lymphoma.

[10]  D. Arber,et al.  Frequency of bcl-2 expression in non-Hodgkin's lymphoma: a study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[11]  D. Weisenburger,et al.  New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Fisher,et al.  Follicular lymphomas: do histologic subtypes predict outcome? , 1997, Hematology/oncology clinics of North America.

[13]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[14]  S. Horning.  Natural history of and therapy for the indolent non-Hodgkin's lymphomas. , 1993, Seminars in oncology.

[15]  M. Ladanyi,et al.  Cytogenetic analysis of 434 consecutively ascertained specimens of non‐Hodgkin's lymphoma: Correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment , 1991, Genes, chromosomes & cancer.

[16]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[17]  M. Oken,et al.  Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. , 1987, The New England journal of medicine.

[18]  Y. Tsujimoto,et al.  Involvement of the bcl-2 gene in human follicular lymphoma. , 1985, Science.

[19]  R. Lukes,et al.  Immunologic characterization of human malignant lymphomas , 1974, Cancer.

[20]  K. Lennert,et al.  Classification of Non-Hodgkin’s Lymphomas , 1974 .

[21]  Cdm Fletcher,et al.  World Health Organization Classification of Tumours , 2002 .

[22]  H. Rappaport,et al.  Tumors of the hematopoietic system , 1966 .